Zymeworks (ZYME) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks has achieved a significant milestone with the FDA’s accelerated approval of Ziihera, a dual HER2-targeted bispecific antibody for HER2-positive biliary tract cancer (BTC). This approval not only validates Zymeworks’ innovative Azymetric™ technology but also secures a $25 million milestone payment from Jazz Pharmaceuticals, with the potential for further financial gains through regulatory milestones.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.